tiprankstipranks
Advertisement
Advertisement

GNLX Stock Latest News

Buy Rating Backed by Pivotal Olvi-Vec Ovarian Cancer Trial Progress and Multi-Indication Upside Potential
RatingsBuy Rating Backed by Pivotal Olvi-Vec Ovarian Cancer Trial Progress and Multi-Indication Upside Potential
5d ago
GNLX
Genelux price target lowered to $20 from $23 at Benchmark
PremiumThe Fly
Genelux price target lowered to $20 from $23 at Benchmark
6d ago
GNLX
Genelux: Advancing Olvi-Vec Pivotal Program and Manufacturing Readiness Underpin Buy Rating and Long-Term Value Upside
PremiumRatings
Genelux: Advancing Olvi-Vec Pivotal Program and Manufacturing Readiness Underpin Buy Rating and Long-Term Value Upside
6d ago
GNLX
Genelux Establishes $100 Million At-The-Market Equity Program
PremiumCompany Announcements
Genelux Establishes $100 Million At-The-Market Equity Program
7d ago
8K
GNLX
Genelux Updates Corporate Presentation for Investors and Stakeholders
PremiumCompany Announcements
Genelux Updates Corporate Presentation for Investors and Stakeholders
2M ago
8K
GNLX
Genelux Announces Underwritten Public Offering to Raise Capital
PremiumCompany AnnouncementsGenelux Announces Underwritten Public Offering to Raise Capital
3M ago
8K
GNLX
Genelux prices 6.67M shares at $3.00 in underwritten public offering
Premium
The Fly
Genelux prices 6.67M shares at $3.00 in underwritten public offering
3M ago
GNLX
Genelux announces common stock offering, no amount given
Premium
The Fly
Genelux announces common stock offering, no amount given
3M ago
GNLX
Genelux data update indicates disease early control, says H.C. Wainwright
PremiumThe Fly
Genelux data update indicates disease early control, says H.C. Wainwright
3M ago
GNLX
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer
PremiumRatings
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer
3M ago
GNLX
Genelux Reports Encouraging Interim Data for Olvi-Vec Trials
PremiumCompany Announcements
Genelux Reports Encouraging Interim Data for Olvi-Vec Trials
3M ago
8K
GNLX
Genelux reports interim data of systemic administration of Olvi-Vec
PremiumThe Fly
Genelux reports interim data of systemic administration of Olvi-Vec
3M ago
GNLX
Genelux Appoints Veteran Oncologist Jason Litten as CMO
PremiumCompany AnnouncementsGenelux Appoints Veteran Oncologist Jason Litten as CMO
3M ago
8K
GNLX
Genelux appoints Jason Litten as CMO
Premium
The Fly
Genelux appoints Jason Litten as CMO
3M ago
GNLX
Genelux Corp’s Promising Oncolytic Virus Advancements and Market Potential Drive Buy Rating
Premium
Ratings
Genelux Corp’s Promising Oncolytic Virus Advancements and Market Potential Drive Buy Rating
5M ago
GNLX
Promising Clinical Developments in Genelux Corp.’s Olvi-Vec Trials Support Buy Rating
PremiumRatings
Promising Clinical Developments in Genelux Corp.’s Olvi-Vec Trials Support Buy Rating
5M ago
GNLX
Genelux reports Q3 EPS (21c), consensus (21c)
PremiumThe Fly
Genelux reports Q3 EPS (21c), consensus (21c)
5M ago
GNLX
Genelux initiated with a Buy at Titan Partners
PremiumThe Fly
Genelux initiated with a Buy at Titan Partners
5M ago
GNLX
Genelux Corp.’s OnPrime Study: A Potential Game-Changer in Ovarian Cancer Treatment
PremiumCompany Announcements
Genelux Corp.’s OnPrime Study: A Potential Game-Changer in Ovarian Cancer Treatment
5M ago
GNLX
Genelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment
PremiumCompany AnnouncementsGenelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment
5M ago
GNLX
Genelux Corp: Strong Buy Rating Backed by Promising Olvi-Vec Developments and Sector Momentum
Premium
Ratings
Genelux Corp: Strong Buy Rating Backed by Promising Olvi-Vec Developments and Sector Momentum
5M ago
GNLX
Genelux price target raised to $20 from $10 at Maxim
Premium
The Fly
Genelux price target raised to $20 from $10 at Maxim
5M ago
GNLX
REPL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >